Plain-English translation of NCT05582837 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a combination of nortriptyline and topiramate—two medications commonly used to treat migraines—can help reduce the symptoms of Meniere's disease. Meniere's disease causes dizziness, hearing loss, and ear fullness that can be very disabling. This medication is being compared against a water-pill combination to see which works better.
Meniere's disease can be difficult to treat, and doctors are looking for new medication combinations that might work better than current options. This medication combination is already used for migraines, so researchers want to test whether it might also help people with Meniere's disease.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth daily for 8 weeks. Your doctor may gradually increase your dose each week if your symptoms don't improve. You'll fill out symptom surveys before starting, weekly during the trial, and at the end. You'll also have regular visits where a researcher will check in on how you're doing, watch for any side effects, and answer your questions about your medication.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States
Sponsor
University of California, Irvine
Enrollment target
~40 participants
Started
August 2022
Primary completion
December 2027
Age range
25 Years – 85 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hamid R Djalilian
University of California, Irvine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.